{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T10:53:13Z","timestamp":1783075993182,"version":"3.54.6"},"reference-count":13,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2014,11,1]],"date-time":"2014-11-01T00:00:00Z","timestamp":1414800000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2014,11]]},"DOI":"10.1016\/j.clinthera.2014.08.003","type":"journal-article","created":{"date-parts":[[2014,9,16]],"date-time":"2014-09-16T14:23:27Z","timestamp":1410877407000},"page":"1638-1649","source":"Crossref","is-referenced-by-count":24,"title":["Influence of CYP3A4 Induction\/Inhibition on the Pharmacokinetics of Vilazodone in Healthy Subjects"],"prefix":"10.1016","volume":"36","author":[{"given":"Ramesh","family":"Boinpally","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nayra","family":"Gad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samir","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonia","family":"Periclou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2014.08.003_bib1","series-title":"Forest Pharmaceuticals Inc. Viibryd\u00ae (vilazodone hydrochloride) tablets: U.S. Prescribing Information","year":"2012"},{"key":"10.1016\/j.clinthera.2014.08.003_bib2","doi-asserted-by":"crossref","first-page":"615","DOI":"10.2165\/11207550-000000000-00000","article-title":"Vilazodone: in major depressive disorder","volume":"25","author":"Frampton","year":"2011","journal-title":"CNS Drugs"},{"key":"10.1016\/j.clinthera.2014.08.003_bib3","doi-asserted-by":"crossref","first-page":"441","DOI":"10.4088\/JCP.10m06596","article-title":"A randomized, double-blind, placebo-controlled, 8-week study of vilazodone, a serotonergic agent for the treatment of major depressive disorder","volume":"72","author":"Khan","year":"2011","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.clinthera.2014.08.003_bib4","doi-asserted-by":"crossref","first-page":"326","DOI":"10.4088\/JCP.08m04637","article-title":"Evidence for efficacy and tolerability of vilazodone in the treatment of major depressive disorder: a randomized, double-blind, placebo-controlled trial","volume":"70","author":"Rickels","year":"2009","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.clinthera.2014.08.003_bib5","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1097\/JCP.0b013e31822c6741","article-title":"A 1-year, open-label study assessing the safety and tolerability of vilazodone in patients with major depressive disorder","volume":"31","author":"Robinson","year":"2011","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.clinthera.2014.08.003_bib6","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s40261-013-0061-5","article-title":"Pharmacokinetics of vilazodone in patients with mild or moderate renal impairment","volume":"33","author":"Boinpally","year":"2013","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.clinthera.2014.08.003_bib7","unstructured":"Longstreth J, Alcorn H, Swan SK, Adams MH, Reed CR. Vilazodone pharmacokinetics in subjects with mild to moderate hepatic impairment. Poster presented at: the 163rd Annual Meeting of the American Psychiatric Association; May 22\u201326, 2010; New Orleans, Louisiana."},{"key":"10.1016\/j.clinthera.2014.08.003_bib8","unstructured":"Flockhart DA. Drug Interactions: Cytochrome P450 Drug Interaction Table. Indiana University School of Medicine (2007). http:\/\/medicine.iupui.edu\/clinpharm\/ddis\/table.aspx. Accessed April 17, 2013."},{"key":"10.1016\/j.clinthera.2014.08.003_bib9","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1128\/CMR.1.2.187","article-title":"Overview of medically important antifungal azole derivatives","volume":"1","author":"Fromtling","year":"1988","journal-title":"Clinical Microbiol Rev"},{"key":"10.1016\/j.clinthera.2014.08.003_bib10","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1177\/0091270003252519","article-title":"The conduct of in vitro and in vivo drug-drug interaction studies: a PhRMA perspective","volume":"43","author":"Bjornsson","year":"2003","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2014.08.003_bib11","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1046\/j.1365-2125.1997.00630.x","article-title":"Carbamazepine treatment induces the CYP3A4 catalysed sulphoxidation of omeprazole, but has no or less effect on hydroxylation via CYP2C19","volume":"44","author":"Bertilsson","year":"1997","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2014.08.003_bib12","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1176\/appi.ajp.2011.10111704","article-title":"The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults","volume":"168","author":"Posner","year":"2011","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.clinthera.2014.08.003_bib13","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1146\/annurev.pharmtox.41.1.535","article-title":"Interindividual variability in inhibition and induction of cytochrome P450 enzymes","volume":"41","author":"Lin","year":"2001","journal-title":"Annu Rev Pharmacol Toxicol"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291814005347?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291814005347?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,4,17]],"date-time":"2022-04-17T04:17:07Z","timestamp":1650169027000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291814005347"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11]]},"references-count":13,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2014,11]]}},"alternative-id":["S0149291814005347"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2014.08.003","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2014,11]]}}}